SSA
REGN icon

Schonfeld Strategic Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,000
Closed -$7.87M – 2506
2025
Q3 		$7.87M Buy
+14,000
New +$7.92M 0.04% 423

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Schonfeld Strategic Advisors's REGN Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 4,759 shares worth $2.97M. The stake represents 0.01% of the portfolio and ranks #869 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in REGN as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in REGN in Q4 2016 and has held it in 27 quarters since. The position peaked at $15.9M in Q4 2024. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Schonfeld Strategic Advisors held 4,759 shares of Regeneron Pharmaceuticals worth $2.97M as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #869 holding.
  • Schonfeld Strategic Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
  • Schonfeld Strategic Advisors's Regeneron Pharmaceuticals position peaked at $15.9M in Q4 2024.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.